| 9.17 -0.15 (-1.61%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.53 | 1-year : | 13.47 |
| Resists | First : | 9.88 | Second : | 11.53 |
| Pivot price | 9.15 |
|||
| Supports | First : | 8.73  |
Second : | 8.02 |
| MAs | MA(5) : | 9.03 |
MA(20) : | 9.13 |
| MA(100) : | 9.3 |
MA(250) : | 10.02 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 44.2 |
D(3) : | 37.6 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 20.55 | Low : | 7.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CRBP ] has closed below upper band by 48.9%. Bollinger Bands are 55.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.38 - 9.43 | 9.43 - 9.47 |
| Low: | 8.8 - 8.87 | 8.87 - 8.92 |
| Close: | 9.08 - 9.18 | 9.18 - 9.25 |
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Sat, 25 Jul 2026
CRBP|Corbus Pharmaceuticals Holdings Inc|Price:9.170|Chg%:-0.150 - TradingKey
Fri, 24 Jul 2026
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Thu, 23 Jul 2026
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Tue, 21 Jul 2026
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch
Mon, 06 Jul 2026
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer - The Globe and Mail
Mon, 06 Jul 2026
Corbus Pharmaceuticals (NASDAQ: CRBP) hires new CMO and details CRB-701, CRB-913 timelines - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 71.7 (%) |
| Shares Short | 1,950 (K) |
| Shares Short P.Month | 1,530 (K) |
| EPS | -5.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.5 % |
| Return on Equity (ttm) | -66.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -74 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -1.6 |
| PEG Ratio | 0 |
| Price to Book value | 1.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|